Why Is NANOBIOTIX S A ADR (NBTX) Stock Up Today?

Nanobiotix shares rose 7.46% to close at $31.55, driven by the release of final data from a Phase 1 clinical trial. The stock gained momentum after the company presented results for its JNJ-1900 therapy in melanoma patients at the 2026 Congress of the European Society for Medical Oncology.

What Happened

Nanobiotix announced updated results from Phase 1 Study 1100 evaluating JNJ-1900, also known as NBTXR3, in combination with immune checkpoint inhibitors. The study focused on patients with anti-PD-1-resistant primary cutaneous melanoma who had received at least two prior lines of therapy. The data demonstrated a 41.7% objective response rate, including four complete responses. Additionally, the study reported a 75% disease control rate and a median overall survival of 17.8 months in this heavily pretreated population. These findings were presented to the medical community at the recent oncology congress, marking a significant update for the company’s lead asset.

What The Data Shows

The stock opened at $31.01, representing a 5.6% gap up from the prior close of $29.36. Trading activity remained light, with volume at 0.0M shares, which is 0.3 times the three-month daily average. The session high reached $31.56 at 11:20 AM ET, while the low was $30.70 at 10:05 AM ET. Over the last eight sessions, the stock has climbed 37.0%, moving from $21.35 to $29.25 before today’s move. The company currently has a market capitalization of $1.5B and remains unprofitable, with trailing twelve-month earnings per share of -1.24. Revenue increased 13.3% over the trailing twelve months, though the net margin stands at -459.5%. The stock trades within a 52-week range of $14.78 to $57.14. Recent activity included seven fresh 52-week highs and two fresh 52-week lows recorded on October 26, 2026.

What To Watch

Investors will monitor the broader coverage of the Phase 1 data as analysts incorporate the new efficacy metrics into their models. The stock’s beta of 0.59 suggests lower volatility relative to the broader market, but the recent sharp price appreciation warrants attention to potential mean reversion or continued momentum following the positive trial results.